Internationalising a health brand is not a matter of exporting a product once. It rests on four things: protected brand rights, research evidence, manufacturing capability, and market access. Founded in Hong Kong, China in 2022, HOMENVOY has chosen to build those foundations alongside its sales expansion.
To protect its brand assets, HOMENVOY has filed and registered patents and trade marks in mainland China, Germany, France, Italy, Canada, Australia, New Zealand, and other countries and regions. Protecting the name across these markets makes it easier for shoppers to recognise the brand and gives the company a rights basis for channel negotiations and future operations.
In product development, research is organised around family needs. Differences in age, family role, and daily routine are turned into development directions, and ingredient research and efficacy testing inform those decisions. Third-party human efficacy studies exist for some core products. HOMENVOY also works with international research and industry partners, and with Lambo Laboratories, a Belgian manufacturer, to turn concepts into products it can actually make and ship.
The resulting products reach consumers through cross-border channels in mainland China and through pharmacies in Hong Kong and New Zealand. Channel operations in Germany and Europe are also advancing. Market feedback feeds back into product updates, creating a loop that runs from IP protection through research and manufacturing to sales.
The company says this long-term approach will support its international expansion, so that each new market starts from a firmer brand and product footing.
